OBJECTIVE: Nephrogenic systemic fibrosis (NSF) is a serious disease affecting renal failure patients. It may be caused by some gadolinium (Gd)-containing contrast agents, including gadodiamide. The study aimed at estimating the prevalence of NSF after gadodiamide exposure for patients with chronic kidney disease (CKD). MATERIALS AND METHODS: Retrospective cohort study of 190 consecutive nephrological patients in different categories of kidney function referred for gadodiamide-enhanced magnetic resonance imaging in the period January 1, 2004 to March 21, 2006. RESULTS: Eighteen patients (18/190; 10%, 95% CI: 6%-15%) were diagnosed with NSF within a mean follow-up period of 29 months (range 16-43 months). All 18 cases had stage 5 CKD (ie, estimated glomerular filtration rate less than 15 mL/min/1.73 m2 or in dialysis therapy) at the time of their gadodiamide exposure. The prevalence of NSF among patients with stage 5 CKD at exposure (n = 102) was 18% (95% CI: 11%-27%). No cases were seen among 88 gadodiamide-exposed patients who had milder degrees of renal insufficiency (prevalence 0%, 95% CI: 0%-4%). CONCLUSIONS: The risk of NSF is unacceptably high among stage 5 CKD patients exposed to gadodiamide.
OBJECTIVE:Nephrogenic systemic fibrosis (NSF) is a serious disease affecting renal failurepatients. It may be caused by some gadolinium (Gd)-containing contrast agents, including gadodiamide. The study aimed at estimating the prevalence of NSF after gadodiamide exposure for patients with chronic kidney disease (CKD). MATERIALS AND METHODS: Retrospective cohort study of 190 consecutive nephrological patients in different categories of kidney function referred for gadodiamide-enhanced magnetic resonance imaging in the period January 1, 2004 to March 21, 2006. RESULTS: Eighteen patients (18/190; 10%, 95% CI: 6%-15%) were diagnosed with NSF within a mean follow-up period of 29 months (range 16-43 months). All 18 cases had stage 5 CKD (ie, estimated glomerular filtration rate less than 15 mL/min/1.73 m2 or in dialysis therapy) at the time of their gadodiamide exposure. The prevalence of NSF among patients with stage 5 CKD at exposure (n = 102) was 18% (95% CI: 11%-27%). No cases were seen among 88 gadodiamide-exposed patients who had milder degrees of renal insufficiency (prevalence 0%, 95% CI: 0%-4%). CONCLUSIONS: The risk of NSF is unacceptably high among stage 5 CKDpatients exposed to gadodiamide.
Authors: Sarina J Dorazio; Pavel B Tsitovich; Kevin E Siters; Joseph A Spernyak; Janet R Morrow Journal: J Am Chem Soc Date: 2011-08-18 Impact factor: 15.419
Authors: A Eilaghi; A Kassner; I Sitartchouk; P L Francis; R Jakubovic; A Feinstein; R I Aviv Journal: AJNR Am J Neuroradiol Date: 2013-05-30 Impact factor: 3.825
Authors: Narasimharao Bhagavathula; Marissa DaSilva; Muhammad N Aslam; Michael K Dame; Roscoe L Warner; Yiru Xu; Gary J Fisher; Kent J Johnson; Richard Swartz; James Varani Journal: Invest Radiol Date: 2009-08 Impact factor: 6.016
Authors: Sameer M Mazhar; Masoud Shiehmorteza; Chad A Kohl; Michael S Middleton; Claude B Sirlin Journal: J Magn Reson Imaging Date: 2009-12 Impact factor: 4.813
Authors: Andreas Boss; Petros Martirosian; Jan Fritz; Ina Kötter; Jörg C Henes; Claus D Claussen; Fritz Schick; Marius Horger Journal: MAGMA Date: 2009-01-27 Impact factor: 2.310